Advertisement

Experimental Treatment for Marburg Virus Shows Promise in Primates — Physician’s First Watch

Medical News |
August 21, 2014

Experimental Treatment for Marburg Virus Shows Promise in Primates

By Kelly Young

Edited by Susan Sadoughi, MD

An experimental treatment resulted in 100% survival in primates infected with Marburg virus, a filovirus — like Ebola — that causes hemorrhagic fever, according to a study in Science Translational Medicine. Currently, there are no Marburg vaccines or treatments approved for human use.

Twenty-one rhesus macaques were infected with lethal doses of Marburg-Angola virus. Sixteen were given 7 daily intravenous doses of the treatment, a lipid-encapsulated, small-interfering RNA that interferes with how the virus grows once it enters a cell.

By day 9, all monkeys given the control treatment had died, whereas all animals given the active treatment survived, even those who didn't start treatment until 72 hours after infection, when clinical symptoms tend to appear.

The researchers, some of whom hold a patent for the therapy studied, previously published research showing that a similar approach protected monkeys from Ebola virus.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement